NASDAQ:RLYP (RLYP) (RLYP) Stock Price, News & Analysis → This company has increased its dividend every year for 54 years (From DTI) (Ad) Free RLYP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$31.99▼$31.9950-Day Range N/A52-Week Range$10.26▼$32.12VolumeN/AAverage Volume2.93 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (RLYP) alerts: Email Address Ad DarwinExplore the Future: Unlock the Top 3 AI Stocks for 2024 ReportEager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.) [Get Your Insights Now] About (RLYP) Stock (NASDAQ:RLYP)Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.Read More Ad DTIDon’t expose yourself to stocks during the weekThe S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.Click here and I’ll give you all the details. RLYP Stock News HeadlinesApril 19, 2024 | msn.comEU Commission seeks feedback on Vifor's commitments in rival's disparagement caseJanuary 13, 2024 | morningstar.comLudwig Enterprises Inc LUDGApril 19, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.October 25, 2023 | investing.comRLYP Historical DataApril 6, 2023 | nasdaq.comTECK October 20th Options Begin TradingApril 5, 2023 | thestreet.comRelypsa Expects Approval Decision Wednesday on Potassium-Lowering DrugApril 4, 2023 | msn.comTwo-wheeler sales plunge to 7-year low in FY23; tractor sales languish as inflation bites rural India hardApril 4, 2023 | msn.comSeason Preview: Defending State Champion Summit High School Girls Lacrosse Team Ready to 'Make It Count'April 19, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.October 28, 2022 | msn.comBruins send Jack Studnicka to Vancouver in a trade that clears roster room, brings back prospectsOctober 27, 2022 | msn.comBrad Marchand makes his season debut for the Bruins against the Red WingsOctober 27, 2022 | msn.comBrad Marchand will make his season debut for Bruins on Thursday vs. Red WingsSeptember 14, 2022 | thestreet.comRelypsa Fielding Takeout Offers, Shares Move HigherAugust 20, 2022 | msn.comKagiso Rabada becomes 7th South African bowler to take 250 Test wickets; joins Ashwin, Steyn in elite listAugust 19, 2022 | msn.com‘Chaotic’ incident on GCT school bus under investigationMay 3, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: More Items Off Cramer's ChecklistMarch 5, 2022 | thestreet.comJim Cramer's Top Stock Picks: GD PTCT RLYP HON PEPSee More Headlines Receive RLYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (RLYP) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:RLYP CUSIPN/A CIK1416792 Webwww.relypsa.com Phone+1-650-4219500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report RLYP Stock Analysis - Frequently Asked Questions What other stocks do shareholders of (RLYP) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (RLYP) investors own include Royalty Pharma (RPRX), Synergy Pharmaceuticals (SGYP), Akorn (AKRX), Novavax (NVAX), Verastem (VSTM), Skechers U.S.A. (SKX), Sarepta Therapeutics (SRPT), Integrated Device Technology (IDTI) and Gilead Sciences (GILD). This page (NASDAQ:RLYP) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (RLYP) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.